Market Newsdesk

Henry Schein to Webcast First Quarter 2026 Conference Call on Tuesday, May 5, 2026, at 8:00 A.M. ET

MELVILLE, N.Y.–(BUSINESS WIRE)–
Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2026 financial results before the stock market opens on Tuesday, May 5, 2026, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Frederick M. Lowery, Chief Executive Officer and Ronald N. South, Senior Vice President and Chief Financial Officer.

Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on the Henry Schein website following the presentation.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company’s network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our main distribution centers.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 34 countries and territories. The Company’s sales reached $13.2 billion in 2025, and have grown at a compound annual rate of approximately 11.0 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260410958316/en/

Investors

Ronald N. South

Senior Vice President and Chief Financial Officer

[email protected]

(631) 843-5500

Graham Stanley

Vice President, Investor Relations and Strategic Finance Project Officer

[email protected]

(631) 843-5500

Media

Tim Vassilakos

Vice President, Global Corporate Communications

[email protected]

(516) 510-0926

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: General Health Medical Devices Health Dental Medical Supplies

MEDIA:

Logo

Advanced Energy Announces First Quarter 2026 Earnings Date on May 4

DENVER–(BUSINESS WIRE)–
Advanced Energy (Nasdaq: AEIS), a global leader in highly engineered, precision power conversion, measurement, and control solutions, will report its first quarter 2026 financial results after the market closes on Monday, May 4, 2026. Management’s quarterly conference call will be held the same day beginning at 4:30 p.m. Eastern Time.

To participate in the live earnings conference call, please dial 877-407-0890 approximately ten minutes prior to the start of the meeting and an operator will connect you. International participants can dial +1-201-389-0918.

A live webcast of the call will be available on the Investors page of the company’s website at ir.advancedenergy.com in the Events & Presentations section. A replay of the conference call will be available approximately two hours following the end of the live event.

About Advanced Energy

Advanced Energy Industries, Inc. (Nasdaq: AEIS) is a global leader in the design and manufacture of highly engineered, precision power conversion, measurement and control solutions for mission-critical applications and processes. Advanced Energy’s power solutions enable customer innovation in complex applications for a wide range of industries including semiconductor equipment, industrial production, medical and life sciences, data center computing, networking and telecommunications. With engineering know-how and responsive service and support for customers around the globe, the company builds collaborative partnerships to meet technology advances, propels growth of its customers and innovates the future of power. Advanced Energy has devoted four decades to perfecting power. It is headquartered in Denver, Colorado, USA.

For more information, visit www.advancedenergy.com.

Advanced Energy | Precision. Power. Performance. Trust.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421898813/en/

For more information, contact:

Andrew Huang

Advanced Energy Industries, Inc.

970-407-6555

[email protected]

KEYWORDS: Colorado United States North America

INDUSTRY KEYWORDS: Semiconductor Engineering Technology Manufacturing Telecommunications Networks

MEDIA:

Logo

Personalis Highlights Clinical Impact of Ultrasensitive ctDNA Monitoring and New Therapy Resistance Tracking at AACR 2026

Podium presentation on NeXT Personal® monitoring neoadjuvant therapy in colorectal cancer;

Real-world data from 10,000 patients reinforce industry-leading sensitivity;

Data presented for a new NeXT Personal feature for monitoring resistance mutations

FREMONT, Calif.–(BUSINESS WIRE)–
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the successful presentation of clinical data at the American Association for Cancer Research (AACR) Annual Meeting. The data, spanning one oral podium presentation and three posters, underscore the use of the NeXT Personal ultrasensitive ctDNA assay in monitoring treatment response, identifying early recurrence, and tracking the emergence of therapy resistance.

Neoadjuvant Monitoring in Colorectal Cancer. A highlight was the oral podium presentation of the NEOPRISM-CRC trial, delivered by Dr. Jiang from the University College London, which utilized NeXT Personal to monitor patients with high-risk stage II-III dMMR/MSI-H colorectal cancer (CRC) receiving neoadjuvant pembrolizumab. In addition to 100% sensitivity for disease at baseline, the study identified three distinct groups of patient response to neoadjuvant treatment: super molecular responders, dynamic molecular responders, and poor molecular responders. Notably, 100% of “super molecular responders”—those who cleared ctDNA by the second cycle of treatment—also achieved pathological complete response (pCR). Conversely, of “poor molecular responders”—patients with relatively stable ctDNA levels during neoadjuvant treatment—100% did not achieve pCR. These findings could provide clinicians with a critical window to adjust treatment strategies prior to surgery. Post-surgery, the test achieved a 100% negative predictive value (NPV) and 100% specificity for disease relapse.

“The data presented at AACR confirm ultrasensitive ctDNA detection with NeXT Personal as a promising therapy monitoring tool in neoadjuvant colorectal cancer treatment,” said Dr. Richard Chen, President and Chief Medical Officer at Personalis. “By measuring molecular response with high resolution, we are providing the tools needed to explore ctDNA-guided management of colorectal cancer patients receiving neoadjuvant therapy.”

Ultrasensitivity in Real-World Data. In a large-scale analysis of nearly 25,000 plasma samples from 10,000 real-world patients, NeXT Personal demonstrated consistent ultrasensitive performance with a median limit of detection of 1.92 PPM. The study also revealed that 39% of all positive MRD detections occurred in the ultrasensitive range below 100 PPM, with 14.6% below 10 PPM—detections that could be missed with less sensitive assays. This study also highlights the robust ultrasensitive performance of the NeXT Personal assay in real-world testing conditions across more than 14 cancer types, stage I-IV disease, and a variety of challenging sample types.

Innovation in Therapy Resistance Tracking. Personalis also debuted analytical validation and real-world data for a new opt-in feature of its NeXT Personal MRD test: Real-Time Variant Tracker™. This feature allows for the simultaneous monitoring of MRD and the longitudinal tracking of specific resistance-associated mutations, such as ESR1. With a specificity of >99.9%, resistance and other clinical mutations were identified in 38% of MRD-positive patients across the real-world cohort, offering a new tool for tracking treatment resistance as it emerges.

Monitoring Immunotherapy Response in NSCLC. The DARWIN 2 study results in metastatic non-small cell lung cancer (NSCLC) demonstrated NeXT Personal’s ability to stratify risk in patients receiving immunotherapy. Patients who achieved a durable molecular complete response (dmCR) remained 100% progression-free at three years, whereas patients who failed to achieve molecular clearance were five times more likely to experience disease progression.

Together, these studies illustrate Personalis’ commitment to improving cancer management through ultrasensitive MRD testing throughout the patient journey.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as “believe,” “expect,” “if,” “may,” “will” or similar expressions. These statements include those relating to: the use, clinical impact or real-world clinical performance of NeXT Personal, the ability of NeXT Personal or the Real-Time Variant Tracker feature to inform cancer monitoring or patient management, predict or track therapy response, detect resistance or other clinical mutations, predict relapse, or predict or impact patient outcomes. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to Personalis’ ability to demonstrate attributes, advantages or clinical validity or utility of the NeXT Personal test and the Real-Time Variant Tracker option, including the NeXT Personal MRD assay remaining unique in its ability to detect traces of cancer in the ultrasensitive range and its ability to monitor mutations; future clinical data differing from the clinical data previously presented or expected results; the rate of adoption and use of the NeXT Personal test; changes in health care policy, which could increase Personalis’ costs, decrease Personalis’ revenue, and impact sales of and reimbursement for Personalis’ tests; the impact of competition and macroeconomic factors on Personalis’ business; the partnering and/or collaboration arrangements that Personalis has entered into or may enter into in the future may not be successful, or may terminate, which could adversely impact Personalis’ business or affect its ability to develop and commercialize its services and products; having a limited number of suppliers; and customer concentration. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Personalis’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 26, 2026. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.

Not affiliated with or endorsed by AACR.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421790003/en/

Investors:

Caroline Corner

[email protected]

415-202-5678

Media Contact:

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Oncology Health Genetics Clinical Trials Pharmaceutical Biotechnology

MEDIA:

Logo

Docebo Announces Preliminary Unaudited Results for the Q1-2026 and Provides Updated Outlook for Fiscal Year 2026

TORONTO–(BUSINESS WIRE)–
Docebo Inc. (NASDAQ: DCBO, TSX: DCBO), the Enterprise Platform for the AI-era workforce, unifying skills intelligence, learning, and knowledge in one closed loop, announced today the following preliminary (unaudited) financial results for the first quarter ended March 31, 2026 (“Q1-2026”), reported in accordance with IFRS Measures (IFRS) and in U.S. dollars. As previously announced, the Company expects to report its full Q1-2026 financial results before the market opens on Friday, May 8, 2026.

“Docebo delivered an exceptional start to 2026, exceeding our expectations across the board and reinforcing the strength of our market positioning. Our performance reflects both disciplined execution and growing demand for our AI workforce readiness platform as organizations prioritize workforce readiness in an increasingly complex operating environment,” said Alessio Artuffo, President and CEO. “With Docebo Inspire beginning today in Miami, we look forward to showcasing innovations that further strengthen our position in the market.”

Preliminary (Unaudited) Q1-2026 Financial Results

Preliminary (unaudited) financial results for the three months ended March 31, 2026 were as follows:

• Total revenue is expected to be between US$65.4 and US$65.6 million, an increase of 14.3% compared to $57.3 million for the first quarter of 2025.

• Adjusted EBITDA¹ is expected to be between US$10.8 and US$11.0 million, an increase of 22.5% compared to US$8.9 million for the first quarter of 2025.

• Annual Recurring Revenue (ARR)¹ is expected to be US$248.9 million as of March 31, 2026, an increase of 10.6% compared to US$225.1 million as of March 31, 2025. ARR was negatively impacted in the quarter by $1.4 million due to the effects of foreign exchange.

• Our largest OEM customer is expected to represent 3.2% of ARR as of March 31, 2026, compared to 9.4% as of March 31, 2025.

• Excluding our largest OEM customer, acquired ARR from acquisitions and after adjusting for the above noted negative impact due to the effects of foreign exchange, ARR increased by approximately 13.7% from the comparative period in the prior year.

¹ Please refer to the “Non-IFRS Measures and Key Performance Indicators” section of this press release.

These estimates are preliminary and are inherently uncertain due to a number of factors. They remain subject to Docebo management and Audit Committee reviews and the completion of regular financial closing and review procedures for the three months ended March 31, 2026. Additional adjustments to the preliminary estimates presented above may be identified, and final results for the relevant fiscal periods may differ materially from these preliminary estimates and will not be finalized until after the Company completes its normal quarter-end accounting procedures, including execution of internal controls over financial reporting. These preliminary estimates are intended to provide information about management’s current expectations regarding certain aspects of Docebo’s financial performance. Reliance on the information presented herein may not be appropriate for other purposes.

Updated Financial Outlook

Additionally, Docebo revised its guidance for the fiscal year ending December 31, 2026 as follows:

	Revised Guidance	Prior Guidance
Total Revenue	$271.0m to $273.0m	$267.5m to $269.5m
Subscription Revenue	$253.5m to $255.5m	$251.5m to $253.5m
Adjusted EBITDA	$54.5m to $56.5m	$52.5m to $54.5m

The information in this section is forward-looking. Please see the sections titled “Non-IFRS Measures and Key Performance Indicators” in this press release for how we define “Adjusted EBITDA” and the section titled “Forward- Looking Information.” Docebo believes that this type of guidance provides useful insight into the anticipated performance of its business.

Investor Briefing at Docebo Inspire Miami – Tuesday, April 21, 2026 – 2p ET

As previously announced, Docebo will present a livestream webcast of its Investor Briefing later today, Tuesday, April 21, 2026 at 2:00 p.m. ET. A live webcast and replay of the presentation will be available at https://www.docebo.inc/home/default.aspx.

Q1-2026 Conference Call and Webcast Information – Friday, May 8, 2026 – 8a ET

Docebo will present a live audio webcast of a conference call to review its Q1-2026 financial results on Friday, May 8, 2026, at 8:00 a.m. ET.

Investors can access the live call by dialing into +1.888.440.6840 or by accessing the webcast which will be available at https://www.docebo.inc/home/default.aspx

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws.

In some cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects”, “is expected”, “an opportunity exists”, “budget”, “scheduled”, “estimates”, “outlook”, “forecasts”, “projection”, “prospects”, “strategy”, “intends”, “anticipates”, “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or, “will”, “occur” or “be achieved”, and similar words or the negative of these terms and similar terminology. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events or circumstances.

This forward-looking information in this press release includes, but is not limited to, statements regarding the Company’s business; statements regarding Docebo’s preliminary estimates for revenue, Adjusted EBITDA and annual recurring revenue for the three months ended March 31, 2026, the revised guidance for fiscal year ending December 31, 2026 in respect of total revenue, Adjusted EBITDA and subscription revenue discussed under “Updated Financial Outlook” in this press release; the impact of AI on our business; our AI Workforce Readiness Platform; future financial position and business strategy; Docebo’s position in the learning management industry; our growth rates and growth strategies; addressable markets for our solutions and the achievement of advances in and expansion of our platform, including new innovations to be showcased at Docebo Inspire. This forward-looking information is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we currently believe are appropriate and reasonable in the circumstances. Despite a careful process to prepare and review the forward-looking information, there can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Certain assumptions include: our ability to build our market share and enter new markets and industry verticals; our ability to attract and retain key personnel; our ability to maintain and expand geographic scope; our ability to execute on our expansion plans, including, but not limited to, our ability to execute on new innovations to be showcased at Docebo Inspire and to expand upon AI components of our platform; our ability to continue investing in infrastructure to support our growth; our ability to obtain and maintain existing financing on acceptable terms; our ability to execute on profitability initiatives; our ability to maintain the authorization required for use of our platform across the public sector; currency exchange and interest rates; the impact of inflation and global macroeconomic conditions; the impact of competition; our ability to respond to the changes and trends in our industry or the global economy; and the changes in laws, rules, regulations, and global standards are material factors made in preparing forward-looking information and management’s expectations.

Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that, while considered by the Company to be appropriate and reasonable as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to:

• the Company’s ability to execute its growth strategies;

• the impact of changing conditions in the global corporate e-learning market;

• increasing competition in the global corporate e-learning market in which the Company operates;

• fluctuations in currency exchange rates and volatility in financial markets;

• changes in the attitudes, financial condition and demand of our target market;

• the Company’s ability to operate its business and effectively manage its growth under evolving macroeconomic conditions, such as high inflation and recessionary environments;

• developments and changes in applicable laws and regulations;

• fluctuations in the length and complexity of the sales cycle for our platform, especially for sales to larger enterprises;

• issues in the use of AI in our platform and potential resulting reputational harm or liability; and

• such other factors discussed in greater detail under the “Risk Factors” section of our Annual Information Form dated February 26, 2026 (“AIF”), which is available under our profile on SEDAR+ at www.sedarplus.ca.

Our guidance for the fiscal year ended December 31, 2026 in respect of total revenue, Adjusted EBITDA and subscription revenue, is in each case subject to certain assumptions and associated risks as stated above under this “Forward-Looking Information,” section and in particular the following:

• foreign exchange rates remain consistent with those in effect as at March 31, 2026;

• macro-economic conditions will be generally consistent with those experienced in 2025;

• 2026 revenue from our largest original equipment manufacturer customer will be approximately 3.7% of 2026 total revenue and 2026 revenue from our recent acquisition of 365Talents will be approximately $9 million;

• does not include any expected new contracts (excluding renewals) greater than $1m ARR in 2026;

• we will maintain our customer retention levels, and specifically, our customers will renew contractual commitments on a periodic basis as those commitments come up for renewal, at rates not materially inconsistent with our historical experience; and

• with respect to Adjusted EBITDA, we will contain expense levels while expanding our business.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information.

Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents our expectations as of the date specified herein, and are subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.

Additional information relating to Docebo, including our AIF, can be found on SEDAR+ at www.sedarplus.ca.

Non-IFRS Measures and Key Performance Indicators

This press release makes reference to certain non-IFRS measures including key performance indicators used by management and typically used by our competitors in the software-as-a-service (“SaaS”) industry. These measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS and are therefore not necessarily comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management’s perspective. Accordingly, these measures should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. These non-IFRS measures are used to provide investors with alternative measures of our operating performance and liquidity and thus highlight trends in our business that may not otherwise be apparent when relying solely on IFRS measures. We also believe that securities analysts, investors and other interested parties frequently use non-IFRS measures, including SaaS industry metrics, in the evaluation of companies in the SaaS industry. Management also uses non-IFRS measures to facilitate operating performance comparisons from period to period, the preparation of annual operating budgets and forecasts and to determine components of executive compensation. The non-IFRS measures referred to in this press release include “Adjusted EBITDA”, and “Annual Recurring Revenue”.

Many of the Adjusted EBITDA figures in this press release are forward-looking in nature. The differences between the Adjusted EBITDA figures in this press release that are forward-looking and the equivalent historical non-IFRS financial measures are generally a result of our expected increase in 2026 revenues, as described above.

For a reconciliation of the first quarter and fiscal year 2025 Adjusted EBITDA figures to their nearest IFRS measure (being net income) please see the section titled “Key Performance Indicators” in the Company’s Management’s Discussion and Analysis for the three months ended March 31, 2025 and the Company’s Management Discussion and Analysis for the Year Ended December 31, 2025, respectively, which sections are incorporated by reference into this press release and is available under our profile on SEDAR+ at www.sedarplus.ca.

We recognize subscription revenues ratably over the term of the subscription period under the provisions of our agreements with customers. The terms of our agreements, combined with high customer retention rates, provides us with a significant degree of visibility into our near-term revenues. Management uses a number of metrics, including the ones identified below, to measure the Company’s performance and customer trends, which are used to prepare financial plans and shape future strategy. Our key performance indicators may be calculated in a manner different than similar key performance indicators used by other companies.

• Annual Recurring Revenue: We define Annual Recurring Revenue as the annualized equivalent value of the subscription revenue of all existing contracts (including Original Equipment Manufacturer contracts) as at the date being measured, excluding non-recurring revenues from implementation, support and maintenance fees. Our customers generally enter into annual or multi-year contracts which are non-cancellable or cancellable with penalty. Accordingly, our calculation of Annual Recurring Revenue assumes that customers will renew the contractual commitments on a periodic basis as those commitments come up for renewal. Subscription agreements may be subject to price increases upon renewal reflecting both inflationary increases and the additional value provided by our solutions. In addition to the expected increase in subscription revenue from price increases over time, existing customers may subscribe for additional features, learners or services during the term. We believe that this measure provides a fair real-time measure of performance in a subscription-based environment. Annual Recurring Revenue provides us with visibility for consistent and predictable growth to our cash flows.

• Adjusted EBITDA: We define Adjusted EBITDA as net income excluding net finance income, depreciation and amortization, income taxes, share-based compensation and related payroll taxes, other income, foreign exchange gains and losses, acquisition related compensation, transaction related expenses and restructuring costs, if any. The IFRS measure most directly comparable to Adjusted EBITDA presented in our financial statements is net income.

About Docebo

Docebo (NASDAQ: DCBO; TSX: DCBO) is redefining how enterprises build human capability at scale. Our AI workforce readiness platform connects skills intelligence, learning execution, and measurable outcomes in a single closed loop, giving organizations the tools to close skills gaps, develop talent, and perform at their best in an AI-driven world.

Learn why businesses around the world love Docebo by visiting our customer stories page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421155421/en/

For further information, please contact:

Mike McCarthy

Vice President – Investor Relations

(214) 830-0641

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Software Human Resources Other Education Artificial Intelligence Professional Services Technology Education Training

MEDIA:

Logo

Synthflow AI and 8×8 Enter Strategic Partnership to Deliver Next-Generation Agentic AI

BERLIN–(BUSINESS WIRE)–Synthflow AI, an enterprise AI agent platform that automates customer conversations, has formed a strategic partnership with 8×8, Inc. (NASDAQ: EGHT), a leading global business communications platform provider, to bring Synthflow next-generation AI agents to enterprise contact centers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421904109/en/

This collaboration integrates Synthflow into the 8×8 Contact Center, automating self-service while enhancing agent support across AI calls, chat, and digital channels. The new technology helps joint customers avoid missing calls, ultimately converting more leads, empowering customers to increase their CSAT scores, and reducing operational costs. Additionally, customers can set up Al answering assistants without developer support.

The global voice AI market is expected to grow to $54 billion by 2033, and this partnership addresses the growing need for modern, enterprise-ready conversational AI. By replacing legacy point solutions, Synthflow enables joint customers to avoid long implementation cycles and complex setups. The platform delivers natural, human-like conversations with low latency, advanced interruption handling, memory capabilities, and support for over 30 languages. These features allow businesses to achieve faster resolution times and higher containment rates.

Hakob Astabatsyan, CEO of Synthflow, said: “Our partnership with 8×8 validates the strength of our agentic AI capabilities and the sophisticated framework we use. Having handled over 65 million voice interactions, we’ve seen firsthand the significant impact that transformative AI has on businesses in driving efficiency, satisfaction, and lowering costs.

“We give 8×8 and Synthflow customers an agile, innovation-focused alternative to legacy systems, making it easier than ever to transform customer interactions with intelligent automation at scale.”

The integration provides a distinct competitive advantage in the cloud contact center market. The long-term strategic alignment also includes future roadmap initiatives, such as enabling 8×8 and its channel partners to resell Synthflow directly, alongside offering the platform to small and medium businesses through the 8×8 App Store.

Victor Belfor, Global Vice President, Business Development and Strategic Partnerships at 8×8, Inc., said: “As consumers become increasingly comfortable engaging with AI agents, it’s vital that our customers recognize this channel as a priority for seamless, effective customer engagement. By partnering with Synthflow, we’re providing joint customers with the modern capabilities they need to help improve their satisfaction scores and quickly implement advanced voice automation.”

To learn more about the partnership, read 8×8’s blog post “From Enterprise AI to Everyone: Why We Partnered with Synthflow.”

About Synthflow AI

Synthflow AI is an enterprise AI agent platform that automates customer conversations across phone and chat. Built for production environments, it combines agent orchestration with its own telephony infrastructure to deliver reliable performance, fast deployment, and full control over the end-to-end conversation flow. A G2 Grid Leader for AI Agents, Synthflow has processed over 65 million customer calls for more than 100 enterprise customers, including Freshworks and Thryv.

About 8×8, Inc.

8×8, Inc. (NASDAQ: EGHT) connects people and organizations through seamless communication on one of the industry’s most integrated platforms for Customer Experience – combining Contact Center, Unified Communications, and CPaaS solutions. The 8×8® Platform for CX integrates AI to enable personalized customer journeys, drive operational excellence and insights, and facilitate team collaboration. As a business communications leader, the company helps customer experience and IT leaders around the world become the heartbeat of their organizations, empowering them to unlock the potential of every interaction. For additional information, visit www.8×8.com, or follow 8×8 on LinkedIn, X, and Facebook.

Caution Concerning Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the expected capabilities and benefits of the Synthflow AI and 8×8 partnership, anticipated improvements in customer engagement and satisfaction through AI-powered voice automation, the expected growth of the global voice AI market, the advantages of integrating Synthflow into the 8×8 Contact Center, and future roadmap initiatives including channel partner resale programs and the 8×8 App Store. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. For a discussion of these risks and uncertainties, please refer to 8×8’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. 8×8 assumes no obligation to update any forward-looking statements to reflect events that occur or circumstances that exist after the date on which they were made.

Copyright 2026 8×8, Inc. 8×8 and associated brand assets are trademarks of 8×8, Inc. All rights reserved.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421904109/en/

Synthflow AI Contacts:

Media: [email protected]

synthflow.ai

8×8, Inc. Contacts:

Media:

PR@8×8.com

Investor Relations:

Investor.Relations@8×8.com

KEYWORDS: Germany Europe Ireland United Kingdom

INDUSTRY KEYWORDS: Technology Venture Capital Telecommunications Professional Services Software Networks Data Management Artificial Intelligence VoIP

MEDIA:

Photo

Synthflow AI and 8×8 Enter Strategic Partnership to Deliver Next-Generation Agentic AI

Logo